

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2008-000901-13/ Novartis Protocol ID CQMF149B2202

*A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler® (250/400 µg q.d. evening) compared to fluticasone propionate/salmeterol (250/50 µg b.i.d.) FSC in patients with Chronic Obstructive Pulmonary Disease (COPD).*

Trial CQMF149B2202 was cancelled with no patient enrollment and as such, no results will be reported.